

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2003/010162
International Filing Date : 12 September 2003 (12.09.2003)
Priority Date(s) Claimed : 13 September 2002 (13.09.2002)
Applicant(s) (DO/EO/US) : Federico BUSSOLINO, ET AL.

Title: A NOVEL MECHANISM FOR HIV-1 ENTRY INTO HOST CELLS AND
PEPTIDES INHIBITING THIS MECHANISM

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- ☒ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - ☒ within three months of the actual filing date of the national phase of a PCT application; OR
 - ☐ before the mailing of a first substantive office action (including after filing of an RCE).
- ☐ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- a final rejection under 37 C.F.R. 1.113;
 - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
 - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
 - ☐ a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
- ☐ Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:
- ☐ a final action under 37 C.F.R. § 1.113;
 - ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
 - ☐ OR a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- ☐ Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- ☒ Copies of materials listed but not attached were cited in an international search report dated September 17, 2004.
- ☐ Not required by 37 CFR § 1.98.
- ☐ Copies of the materials listed are attached (except for the foregoing).

Non-English Language References

☒ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).

☐ A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone

Y = document of particular relevance when it is combined with another such document

A = document defining the general state of the art

O = non-written disclosure

P = intercalated document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

☐ Translation of other relevant information on foreign search report

Other Information


Payment of Fees Due (If Any):

☐ A check for \$_____ covering the fee identified above is attached.

☐ Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

☒ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: WEICKM-0043

Date: March 14, 2005

AJZ:ssr

DT15 Rec'd PCT/FTO 14 MAR 2005

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	USNP of PCT/EP2003/010162
Filing Date	12 September 2003 (12.09.2003)
First Named Inventor	Federico BUSSOLINO ET AL.
Group Art Unit	unknown
Examiner Name	unknown
Attorney Docket Number	WEICKM-0043

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
		Application Number	USNP of PCT/EP2003/010162		
		Filing Date	12 September 2003 (12.09.2003)		
		First Named Inventor	Federico BUSSOLINO, ET AL.		
		Group Art Unit	unknown		
		Examiner Name	unknown		
		Attorney Docket Number	WEICKM-0043		
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	004	O'BRIEN W A ET AL: "ANTI-HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ACTIVITY OF AN OLIGOCATIONIC COMPOUND MEDIATED VIA gp120 V3 INTERACTIONS." JOURNAL OF VIROLOGY, UNITED STATES MAY 1996, vol. 70, no. 5, pages 2825-2831	
	005	DE CLERCQ ERIK: "NEW DEVELOPMENTS IN ANTI-HIV CHEMOTHERAPY." BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1587, no. 2-3, 18 July 2002, pages 258-275	
	006	CAFARO A ET AL: "CONTROL OF SHIV-89.6P-INFECTION OF CYNOMOLGUS MONKEYS BY HIV-1 TAT PROTEIN VACCINE." NATURE MEDICINE. UNITED STATES JUN 1999, vol. 5, no. 6, pages 643-650	
	007	DE WOLF F ET AL: "CHARACTERIZATION OF HUMAN ANTIBODY-BINDING SITES ON THE EXTERNAL ENVELOPE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 2." THE JOURNAL OF GENERAL VIROLOGY. ENGLAND June 1991, vol. 72, pages 1261-1267	
	008	MODROW S ET AL.: "USE OF SYNTHETIC OLIGOPEPTIDES IN IDENTIFICATION AND CHARACTERIZATION OF IMMUNOLOGICAL FUNCTIONS IN THE AMINO ACID SEQUENCE OF THE ENVELOPE PROTEIN OF HIV-1: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, RAVEN PRESS, NEW YORK, US vol. 2, no. 1, 1989, pages 21-27	
	009	DAVIS D ET AL.: "ANTISERA RAISED AGAINST THE SECOND VARIABLE REGION OF THE EXTERNAL ENVELOPE GLYCOPROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CROSS-NEUTRALIZE AND SHOW AN INCREASED NEUTRALIZATION INDEX WHEN THEY ACT TOGETHER WITH ANTISERA TO THE V3 NEUTRALIZATION EPITOPE." THE JOURNAL OF GENERAL VIROLOGY. ENGLAND DEC 1993, vol. 74, December 1993, pages 2609-2617	
	010	SURMAN S ET AL: "LOCALIZATION OF CD4+ T CELL EPITOPE HOTSPOTS TO EXPOSED STRANDS OF HIV ENVELOPE GLYCOPROTEIN SUGGESTS STRUCTURAL INFLUENCES ON ANTIGEN PROCESSING." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. vol. 98, no. 8, 10 April 2001, pages 4587-4592	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.